Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Cardiogen

Ala-Glu-Asp-Arg (AEDR) Cardiac Peptide Bioregulator

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

Cardiogen (AEDR, Ala-Glu-Asp-Arg) rests entirely on preclinical work from Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, chiefly organotypic and in-vitro cardiac tissue-culture studies reporting increased cytoskeletal and nuclear-matrix protein synthesis and suppression of p53-linked cardiomyocyte apoptosis, described in Khavinson-group reviews such as PMID 31808038 and PMID 23734519. No published, independently replicated human randomized controlled trial exists, so the honest grade is 1 (animal/in-vitro only), not 2.

FDA
Not Approved (USA); sold research-use-only, unapproved as a drug
WADA
Not listed on the WADA Prohibited List

Reference only. Not medical advice.

What can go wrong

Unapproved research chemical; evidence is Russian-only, preclinical and unreplicated, with no human RCT and no independent Western safety data.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about Cardiogen. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A Khavinson short-peptide (cytogen) heart bioregulator with the sequence Ala-Glu-Asp-Arg (AEDR). Russian preclinical, in-vitro and animal data describe effects on cardiac gene expression, cytoskeletal protein synthesis and cardiomyocyte apoptosis, with no independent replication and no published human RCTs.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Cardiac-aging biology
  • Longevity protocol

How it is supposed to work

Cardiogen is a synthetic peptide (alanine, glutamic acid, aspartic acid, arginine) targeting the heart and blood vessels, promoted for cardiovascular maintenance in the bioregulator framework. Its proposed organ-specific gene-regulation mechanism is unproven in controlled human studies.

Cardiogen is a synthetic short peptide, a defined-sequence second-generation bioregulator built to target cardiac tissue, part of the same organ-by-organ system as the brain peptide Pinealon and the vascular peptide Vesugen.

Type
Synthetic short peptide
Target
Heart muscle
Generation
Second (defined)
Use
Pulsed courses
Evidence
Preclinical and Russian
Western RCT
None

A Heart Bioregulator On The Familiar Single-Lab Evidence

Cardiogen shares the family’s mechanism and the family’s evidence problem without exception. The proposed action is the signature one, a short peptide entering cells to retune the gene expression of its target tissue, here the heart, toward a more youthful pattern, and that proposal is not established outside the originating group. The cardioprotective and repair claims are preclinical and Russian, with no independent human trials, and heart disease is precisely the domain where unverified self-administered compounds are most dangerous, because effective, well-proven cardiovascular treatments already exist and delay is costly. Cardiogen is a plausible-sounding idea on an unreplicated evidence base, in a field where that gap carries real risk.

Safety in detail

Cardiogen has no FDA or EMA approval and no published human randomized controlled trial. Purity, dosing and long-term safety in humans are uncharacterized outside vendor claims, and any positive cardiovascular effects reported come from the developing institute rather than independent trials.

  • Reported safety in decades of Russian clinical use is described as clean, with few serious adverse events, but that record comes largely from within the same research tradition that developed the peptides and has not been independently verified in Western trials.
  • Long-term safety in rigorous, controlled human studies is essentially uncharacterized outside that tradition.
  • Most material sold internationally is gray-market or supplement-grade, so unverified identity, dose and purity are the dominant practical risks.
  • Not FDA-approved for any use; claims of disease treatment are not supported by Western regulatory review.

Children and teenagers

Cardiogen has no validated pediatric use and is an unapproved injected peptide. There is no appropriate pediatric use.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Cardiogen reaches users only through the bioregulator gray market and longevity vendors selling the Khavinson line. There is no approved product, and its market rests on the family’s reputation rather than cardiac evidence.

How we got here

Cardiogen is one of the tissue-targeted short peptide bioregulators developed from the 1970s onward by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, the heart-directed member of a family that also includes Cortagen (brain), Vesugen (vessels), Chonluten (lung) and Epitalon (pineal). The family began as peptide extracts isolated from animal organs and was later reduced to defined synthetic ultra-short sequences, with Cardiogen assigned the tetrapeptide Ala-Glu-Asp-Arg (AEDR). In Russia it is sold as a registered Cardiogen(R) oral capsule in the Cytogen product line by TD Peptid Bio in partnership with the institute and marketed there for cardiovascular indications, while in Western markets the same molecule circulates only as a research-use-only injectable or vendor peptide with no FDA or EMA approval.

Cardiogen was developed as a defined-sequence organ bioregulator at the St. Petersburg institute, extending Khavinson’s tissue-by-tissue approach to the heart.

The numbers behind the grade

Type
Peptide (Ala-Glu-Asp-Arg)
Target
Heart / vessels
Russia
Bioregulator line
FDA
Not approved
Evidence
Single-tradition
Western RCTs
None

The people taking it

A niche cardiovascular bioregulator within the Khavinson Cytogen line, used mainly by dedicated longevity-protocol followers.

Cardiogen’s users are longevity enthusiasts focused on heart aging and the bioregulator-protocol community running organ-peptide courses.

Used as a cardiovascular-support bioregulator, almost entirely within Russian-tradition longevity protocols.

Set against the alternatives

Cardiogen is the cardiac entry in the same organ-targeted system as the vascular peptide Vesugen and the brain peptide Pinealon, and it shares Epithalon’s longevity framing applied to the heart. Unlike genuinely evidence-based cardiovascular peptides and drugs, its support is preclinical and confined to one lineage. The contrast with proven cardiac care is the most important thing about it.

What we do not know

  • Whether independent, Western randomized trials confirm any of the claimed clinical effects.
  • Whether the proposed DNA-binding, gene-regulating mechanism actually operates in human tissue at the doses used.
  • Why, after forty years and hundreds of papers, replication outside the originating institute remains so limited.
  • Whether results from complex tissue extracts (Cytomaxes) translate to the defined synthetic peptides (Cytogens) sold alongside them.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Available internationally as oral or injectable bioregulator supplements (Cytogen and Cytomax lines) and as research-use-only peptide vials, with legal status varying by country. None is an FDA-approved medicine, so there is no regulated US prescription route; the honest course is to treat the claims with caution and consult a clinician.

Material reaches international buyers two ways: as branded Cytogen (synthetic) or Cytomax (animal-tissue extract) supplements produced in Russia, and as research-use-only vials, much of it synthesized in China. Neither route guarantees the identity or potency the label claims, so an independent certificate of analysis is the only real check and is uncommon.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Cardiogen.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Supply chain. We have not mapped where it is made.
  • What could change. No forward-looking summary yet.

Sources

The studies that matter

  • Khavinson group studies2000s-2010s

    Reported cardiovascular and vascular effects within the bioregulator research program.

  • Independent replicationnone notable

    No independent Western trials of Cardiogen have been published.